BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 8525771)

  • 1. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
    Pawelski S
    Acta Haematol Pol; 1995; 26(3):263-8. PubMed ID: 8525771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
    Foo WC; Huang Q; Sebastian S; Hutchinson CB; Burchette J; Wang E
    Hum Pathol; 2010 Dec; 41(12):1802-8. PubMed ID: 20869749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
    Briones J; Montserrat E; Urbano-Ispizua A; Esteve J; Colomer D; López-Guillermo A; Bosch F; Hadjieu E; Rozman C
    Med Clin (Barc); 1996 Jun; 107(3):86-9. PubMed ID: 8754493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
    Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment.
    Shields DJ; Byrd JC; Abbondanzo SL; Lichy JH; Diehl LF; Aguilera NI
    Mod Pathol; 1997 Nov; 10(11):1151-9. PubMed ID: 9388067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
    Varga F; Lehoczky D; Demeter J
    Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine in the treatment of lymphoproliferative malignancies.
    Feldman EJ; Keating MJ
    Cancer Invest; 1993; 11(3):314-8. PubMed ID: 8485654
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
    Juliusson G; Elmhorn-Rosenborg A; Liliemark J
    N Engl J Med; 1992 Oct; 327(15):1056-61. PubMed ID: 1355853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.
    Xu W; Miao KR; Hong M; Zhu DX; Fang C; Dong HJ; Wang DM; Cao X; Li JY
    Eur J Cancer; 2010 Aug; 46(12):2145-9. PubMed ID: 20627536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma.
    Oken MM
    Cancer; 1992 Aug; 70(4 Suppl):946-8. PubMed ID: 1638466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine for chronic lymphocytic leukemia.
    Erman M; Celik I; Tekuzman G
    N Engl J Med; 2001 Apr; 344(15):1166; author reply 1167-8. PubMed ID: 11302142
    [No Abstract]   [Full Text] [Related]  

  • 14. Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.
    Richards S
    Cancer Treat Rev; 2005 Jun; 31(4):332-5. PubMed ID: 15894429
    [No Abstract]   [Full Text] [Related]  

  • 15. Fludarabine in lymphoproliferative malignancies: a single-centre experience.
    Prabhash K; Vikram GS; Nair R; Sengar M; Gujral S; Bakshi A; Gupta S; Parikh PM
    Natl Med J India; 2008; 21(4):171-4. PubMed ID: 19267037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG; Flynn JM; Howard RS; Byrd JC
    Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine in low-grade lymphoma.
    Pigaditou A; Rohatiner AZ; Whelan JS; Johnson PW; Ganjoo RK; Rossi A; Norton AJ; Amess J; Lim J; Lister TA
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):24-7. PubMed ID: 8235692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
    Lam CC; Ma ES; Kwong YL
    Am J Hematol; 2005 Aug; 79(4):288-90. PubMed ID: 16044456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
    Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
    Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.